New Delhi, Mar 18 (TNT): Mankind Pharma Limited on Wednesday announced the acquisition of the Rivotril brand from Roche for the Indian market, securing exclusive rights to manufacture, market and distribute the product across the country.
Rivotril, the innovator brand of clonazepam, is widely prescribed for neurological and psychiatric conditions and is regarded as a “textbook” brand with strong clinical legacy and recall among specialists.
The acquisition is aimed at strengthening Mankind Pharma’s presence in the central nervous system (CNS) therapy segment and aligns with its broader strategy to expand in chronic and specialty therapies, the Pharmaceutical company said in a release..
The company said chronic therapies are contributing an increasing share to its overall business, supported by new launches, in-licensing partnerships and portfolio expansion across key therapeutic areas.
Senior President, Sales and Marketing (Specialty Business), Atish Majumdar said the acquisition would help deepen the company’s presence in CNS therapies and create opportunities for future growth through potential line extensions catering to evolving patient and physician needs.
He said it will leverage its nationwide distribution network and field force to expand access to the brand across healthcare institutions and prescribers.
The company engages with over five lakh doctors across India and has established a strong presence in both urban and semi-urban markets.
The addition of Rivotril is expected to enhance treatment options for patients managing neurological conditions while strengthening the company’s specialty portfolio.
TNT KS
Leave a Reply